Verrica制药公司正积极推进其候选药物VP-315的开发进程。该药物针对基底细胞癌的治疗,预计将在2026年进入关键的第三阶段临床试验计划。这一进展标志着公司在皮肤病治疗领域的重要步伐。
Verrica制药公司正积极推进其候选药物VP-315的开发进程。该药物针对基底细胞癌的治疗,预计将在2026年进入关键的第三阶段临床试验计划。这一进展标志着公司在皮肤病治疗领域的重要步伐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.